Joel Picus

Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma.

Authors:

Andrew J Armstrong Andrew B Nixon Andrea Carmack Timothy Eisen Walter M Stadler Robert J Jones Jorge Garcia Ulka N Vaishampayan Joel Picus Robert E Hawkins John D Hainsworth Christian Kollmannsberger Theodore F Logan Igor Puzanov Lisa Pickering Christopher W Ryan Andrew Protheroe Daniel J George Susan Halabi

Clin Cancer Res 2021 Feb 16. Epub 2021 Feb 16.

Biostatistics and Bioinformatics, Duke Medical Center.

View Article and Find Full Text PDF

February 2021

Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy.

Clin Genitourin Cancer 2021 02 22;19(1):41-46.e1. Epub 2020 Jun 22.

Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address:

View Article and Find Full Text PDF

February 2021

Cell-free DNA alterations in the enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer.

Authors:

Ha X Dang Pradeep S Chauhan Haley Ellis Wenjia Feng Peter K Harris Grace Smith Mark Qiao Katherine Dienstbach Rachel Beck Andrew Atkocius Faridi Qaium Jingqin Luo Jeff M Michalski Joel Picus Russell K Pachynski Christopher A Maher Aadel A Chaudhuri

JCO Precis Oncol 2020 18;4:680-713. Epub 2020 Jun 18.

Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.

View Article and Find Full Text PDF

June 2020

Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate.

Authors:

Hal A Lewis David Y Chen Ilana S Rosman Joel Picus Milan J Anadkat

Dermatol Online J 2020 Jun 15;26(6). Epub 2020 Jun 15.

Division of Dermatology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO.

View Article and Find Full Text PDF

June 2020

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.

J Clin Oncol 2020 06 9;38(16):1797-1806. Epub 2020 Apr 9.

Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.

View Article and Find Full Text PDF

June 2020

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2019 12;17(12):1529-1554

28National Comprehensive Cancer Network.

View Article and Find Full Text PDF

December 2019

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Authors:

Daniel J George Colin Hessel Susan Halabi M Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Michael J Morris Toni K Choueiri

Oncologist 2019 11 9;24(11):1497-1501. Epub 2019 Aug 9.

Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.

View Article and Find Full Text PDF

November 2019

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Authors:

Manik Amin Monica Desai Kathryn Trinkaus Amberly Brown Andrea Wang-Gillam Benjamin Tan Joel Picus Steven Sorscher Maureen Highkin Kim Lears Albert C Lockhart

J Gastrointest Oncol 2019 Jun;10(3):412-420

Division of Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.

View Article and Find Full Text PDF

June 2019

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.

Authors:

Susan Slovin Syed Hussain Fred Saad Jorge Garcia Joel Picus Roberta Ferraldeschi Mateus Crespo Penelope Flohr Ruth Riisnaes Chihche Lin Harold Keer Aram Oganesian Paul Workman Johann de Bono

Clin Cancer Res 2019 08 21;25(15):4624-4633. Epub 2019 May 21.

The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

View Article and Find Full Text PDF

August 2019

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.

Clin Transl Radiat Oncol 2019 Feb 12;15:38-41. Epub 2018 Dec 12.

Washington University in St. Louis, Department of Radiation Oncology, St. Louis, MO, United States.

View Article and Find Full Text PDF

February 2019

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Authors:

Petros Grivas Amir Mortazavi Joel Picus Noah M Hahn Matthew I Milowsky Lowell L Hart Ajjai Alva Joaquim Bellmunt Sumanta K Pal Richard M Bambury Peter H O'Donnell Sumati Gupta Elizabeth A Guancial Guru P Sonpavde Demiana Faltaos Diane Potvin James G Christensen Richard C Chao Jonathan E Rosenberg

Cancer 2019 02 20;125(4):533-540. Epub 2018 Dec 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article and Find Full Text PDF

February 2019

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].

Authors:

Toni K Choueiri Colin Hessel Susan Halabi Ben Sanford M Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J Morris

Eur J Cancer 2018 11 27;103:287. Epub 2018 Sep 27.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF

November 2018

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Br J Cancer 2018 05 16;118(11):1434-1441. Epub 2018 May 16.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article and Find Full Text PDF

May 2018

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Authors:

Toni K Choueiri Colin Hessel Susan Halabi Ben Sanford M Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J Morris

Eur J Cancer 2018 05 20;94:115-125. Epub 2018 Mar 20.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF

May 2018

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

Eur Urol 2018 06 21;73(6):847-855. Epub 2018 Feb 21.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article and Find Full Text PDF

June 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Authors:

Christos E Kyriakopoulos Yu-Hui Chen Michael A Carducci Glenn Liu David F Jarrard Noah M Hahn Daniel H Shevrin Robert Dreicer Maha Hussain Mario Eisenberger Manish Kohli Elizabeth R Plimack Nicholas J Vogelzang Joel Picus Matthew M Cooney Jorge A Garcia Robert S DiPaola Christopher J Sweeney

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article and Find Full Text PDF

April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Authors:

Lauren C Harshman Yu-Hui Chen Glenn Liu Michael A Carducci David Jarrard Robert Dreicer Noah Hahn Jorge A Garcia Maha Hussain Daniel Shevrin Mario Eisenberger Manish Kohli Elizabeth R Plimack Matthew Cooney Nicholas J Vogelzang Joel Picus Robert Dipaola Christopher J Sweeney

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article and Find Full Text PDF

February 2018

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:

Toni K Choueiri Susan Halabi Ben L Sanford Olwen Hahn M Dror Michaelson Meghara K Walsh Darren R Feldman Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Daniel J George Michael J Morris

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article and Find Full Text PDF

February 2017

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Oncotarget 2017 May;8(21):35326-35338

Johns Hopkins University, Baltimore, MD, USA.

View Article and Find Full Text PDF

May 2017

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Authors:

Nabil Adra Costantine Albany Mary J Brames Somer Case-Eads Cynthia S Johnson Ziyue Liu Christopher A Fausel Timothy Breen Nasser H Hanna Ralph J Hauke Joel Picus Lawrence H Einhorn

Support Care Cancer 2016 07 2;24(7):2837-42. Epub 2016 Feb 2.

Division of Hematology/Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN, 46202, USA.

View Article and Find Full Text PDF

July 2016

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Lancet Oncol 2016 Mar 13;17(3):378-388. Epub 2016 Jan 13.

Duke University and the Duke Cancer Institute, Durham, NC, USA.

View Article and Find Full Text PDF

March 2016

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Authors:

A Craig Lockhart Yongjian Liu Farrokh Dehdashti Richard Laforest Joel Picus Jennifer Frye Lauren Trull Stefanie Belanger Madhuri Desai Syed Mahmood Jeanne Mendell Michael J Welch Barry A Siegel

Mol Imaging Biol 2016 06;18(3):446-53

Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St. Louis, MO, 63110, USA.

View Article and Find Full Text PDF

June 2016

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:

Christopher J Sweeney Yu-Hui Chen Michael Carducci Glenn Liu David F Jarrard Mario Eisenberger Yu-Ning Wong Noah Hahn Manish Kohli Matthew M Cooney Robert Dreicer Nicholas J Vogelzang Joel Picus Daniel Shevrin Maha Hussain Jorge A Garcia Robert S DiPaola

N Engl J Med 2015 Aug 5;373(8):737-46. Epub 2015 Aug 5.

From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

View Article and Find Full Text PDF

August 2015

A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

Authors:

May Cho Andrea Wang-Gillam Robert Myerson Feng Gao Steven Strasberg Joel Picus Steven Sorscher Chloe Fournier Gayathri Nagaraj Parag Parikh Rama Suresh David Linehan Benjamin R Tan

HPB (Oxford) 2015 Jul 20;17(7):587-93. Epub 2015 Mar 20.

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article and Find Full Text PDF

July 2015

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Authors:

Jaime R Merchan Rui Qin Henry Pitot Joel Picus Glenn Liu Tom Fitch William J Maples Patrick J Flynn Briant F Fruth Charles Erlichman

Cancer Chemother Pharmacol 2015 Mar 3;75(3):485-93. Epub 2015 Jan 3.

Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW. 12 Avenue. Suite 3400, Miami, FL, 33136, USA,

View Article and Find Full Text PDF

March 2015

Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.

Authors:

Laura W Goff Nilay Thakkar Liping Du Emily Chan Benjamin R Tan Dana B Cardin Howard L McLeod Jordan D Berlin Barbara Zehnbauer Chloe Fournier Joel Picus Andrea Wang-Gillam Wooin Lee A Craig Lockhart

PLoS One 2014 18;9(9):e107424. Epub 2014 Sep 18.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States of America.

View Article and Find Full Text PDF

June 2015

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Authors:

Andrea Wang-Gillam Nilay Thakkar A Craig Lockhart Kerry Williams Maria Baggstrom Michael Naughton Rama Suresh Cynthia Ma Benjamin Tan Wooin Lee Xuntian Jiang Tibu Mwandoro Lauren Trull Stefanie Belanger Allison N Creekmore Feng Gao Paula M Fracasso Joel Picus

Cancer Chemother Pharmacol 2014 Aug 11;74(2):419-26. Epub 2014 Jun 11.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8056, St. Louis, MO, 63110, USA.

View Article and Find Full Text PDF

August 2014